ClinicalTrials.gg
CompletedNCT00346827Updated Jul 10, 2019

Apomorphine Nasal Powder in the Treatment of Parkinson's Disease "Off" Periods.

A Phase 2/3 interventional study of Apomorphine Nasal Powder in Parkinson's Disease, sponsored by Britannia Pharmaceuticals Ltd.. Completed. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2019-07-10.

Sponsored by Britannia Pharmaceuticals Ltd. · Phase 2/3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
36
Ages
18 Years to 85 Years
Sex
All
01

Study summary

To determine the safety and tolerability of repeated dosing with Apomorphine Nasal Powder in subjects with Parkinson's Disease.

02

Conditions studied

  • Parkinson's Disease

Browse trials for

03

In context

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

This study's enrollment of 36 is close to the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.

Browse Parkinson Disease studies →

Lead sponsor

Britannia Pharmaceuticals Ltd. is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1 year history of Parkinson's Disease; stable PD medications for 4 weeks; at least one documented "off" period per day

Exclusion criteria

Exclusion Criteria:

  • to apomorphine; participation in a clinical trial in the last 12 weeks; pregnant or lactating females
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
36 participants (actual)

Interventions

  • DrugApomorphine Nasal Powder
06

Study locations

No study locations are listed for this record.

07

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2006 to primary completion in Aug 2007, 13 months.

Of 22 phase 2/3 interventional studies under Parkinson Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 50. This study's 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2006
First posted
Jun 30, 2006
StartActual
Jul 2006
Primary completionActual
Aug 2007
CompletionActual
Aug 2007
Last update
Jul 10, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00346827
Lead sponsor
Britannia Pharmaceuticals Ltd.
First posted
Jun 30, 2006
Start date
Jul 2006
Primary completion
Aug 2007
Completion
Aug 2007
Last update
Jul 10, 2019

Study contacts

Richard Weiser, MB, MRCP
principal investigator · Swansea Hospital, Swansea, Wales
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion